These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
266 related articles for article (PubMed ID: 16556632)
1. Incidence of voriconazole hepatotoxicity during intravenous and oral treatment for invasive fungal infections. den Hollander JG; van Arkel C; Rijnders BJ; Lugtenburg PJ; de Marie S; Levin MD J Antimicrob Chemother; 2006 Jun; 57(6):1248-50. PubMed ID: 16556632 [TBL] [Abstract][Full Text] [Related]
2. Oral voriconazole for empiric antifungal treatment in patients with uncomplicated febrile neutropenia. Przepiorka D; Buadi FK; McClune B Pharmacotherapy; 2008 Jan; 28(1):58-63. PubMed ID: 18154475 [TBL] [Abstract][Full Text] [Related]
3. A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML). Vehreschild JJ; Böhme A; Buchheidt D; Arenz D; Harnischmacher U; Heussel CP; Ullmann AJ; Mousset S; Hummel M; Frommolt P; Wassmer G; Drzisga I; Cornely OA J Infect; 2007 Nov; 55(5):445-9. PubMed ID: 17822770 [TBL] [Abstract][Full Text] [Related]
4. Voriconazole: new preparation. Invasive aspergillosis: benefits to be confirmed. Prescrire Int; 2004 Feb; 13(69):13-6. PubMed ID: 15055210 [TBL] [Abstract][Full Text] [Related]
5. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Pascual A; Calandra T; Bolay S; Buclin T; Bille J; Marchetti O Clin Infect Dis; 2008 Jan; 46(2):201-11. PubMed ID: 18171251 [TBL] [Abstract][Full Text] [Related]
6. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study. Lazarus HM; Blumer JL; Yanovich S; Schlamm H; Romero A J Clin Pharmacol; 2002 Apr; 42(4):395-402. PubMed ID: 11936564 [TBL] [Abstract][Full Text] [Related]
7. Administration of voriconazole in patients with renal dysfunction. Neofytos D; Lombardi LR; Shields RK; Ostrander D; Warren L; Nguyen MH; Thompson CB; Marr KA Clin Infect Dis; 2012 Apr; 54(7):913-21. PubMed ID: 22267716 [TBL] [Abstract][Full Text] [Related]
8. Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: a prospective study. Soler-Palacín P; Frick MA; Martín-Nalda A; Lanaspa M; Pou L; Roselló E; de Heredia CD; Figueras C J Antimicrob Chemother; 2012 Mar; 67(3):700-6. PubMed ID: 22190607 [TBL] [Abstract][Full Text] [Related]
9. Pharmacoeconomics of voriconazole in the management of invasive fungal infections. Al-Badriyeh D; Heng SC; Neoh CF; Slavin M; Stewart K; Kong DC Expert Rev Pharmacoecon Outcomes Res; 2010 Dec; 10(6):623-36. PubMed ID: 21155694 [TBL] [Abstract][Full Text] [Related]
10. Utilisation, efficacy and safety of voriconazole: prospective, non-interventional study on treatment of IFIs in clinical practice. Heinz WJ; Silling G; Böhme A Curr Med Res Opin; 2011 Feb; 27(2):335-42. PubMed ID: 21155707 [TBL] [Abstract][Full Text] [Related]
11. Topical and oral voriconazole in the treatment of fungal keratitis. Bunya VY; Hammersmith KM; Rapuano CJ; Ayres BD; Cohen EJ Am J Ophthalmol; 2007 Jan; 143(1):151-3. PubMed ID: 17188052 [TBL] [Abstract][Full Text] [Related]
12. Voriconazole as therapy for systemic Penicillium marneffei infections in AIDS patients. Supparatpinyo K; Schlamm HT Am J Trop Med Hyg; 2007 Aug; 77(2):350-3. PubMed ID: 17690411 [TBL] [Abstract][Full Text] [Related]
13. Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections. Pascual A; Csajka C; Buclin T; Bolay S; Bille J; Calandra T; Marchetti O Clin Infect Dis; 2012 Aug; 55(3):381-90. PubMed ID: 22610925 [TBL] [Abstract][Full Text] [Related]
14. Oral voriconazole versus intravenous low dose amphotericin B for primary antifungal prophylaxis in pediatric acute leukemia induction: a prospective, randomized, clinical study. Mandhaniya S; Swaroop C; Thulkar S; Vishnubhatla S; Kabra SK; Xess I; Bakhshi S J Pediatr Hematol Oncol; 2011 Dec; 33(8):e333-41. PubMed ID: 22042283 [TBL] [Abstract][Full Text] [Related]
16. Institutional experience with voriconazole compared with liposomal amphotericin B as empiric therapy for febrile neutropenia. Shehab N; DePestel DD; Mackler ER; Collins CD; Welch K; Erba HP Pharmacotherapy; 2007 Jul; 27(7):970-9. PubMed ID: 17594202 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Denning DW; Ribaud P; Milpied N; Caillot D; Herbrecht R; Thiel E; Haas A; Ruhnke M; Lode H Clin Infect Dis; 2002 Mar; 34(5):563-71. PubMed ID: 11807679 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of hepatotoxicity with off-label oral-treatment doses of voriconazole for invasive fungal infections. Gorski E; Esterly JS; Postelnick M; Trifilio S; Fotis M; Scheetz MH Antimicrob Agents Chemother; 2011 Jan; 55(1):184-9. PubMed ID: 20974867 [TBL] [Abstract][Full Text] [Related]
19. Case collection study of the safety of AmBisome in association with voriconazole in the treatment of patients with invasive fungal infection. Askari E; Jarque I; Nicolás Franco S; Cáceres Agra JJ Rev Esp Quimioter; 2010 Dec; 23(4):210-2. PubMed ID: 21191561 [No Abstract] [Full Text] [Related]
20. Clinical application of voriconazole concentrations in the treatment of invasive aspergillosis. Howard A; Hoffman J; Sheth A Ann Pharmacother; 2008 Dec; 42(12):1859-64. PubMed ID: 19017830 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]